Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
MTZ-Fachkongress

Antriebe und Energiesysteme von morgen


Austausch von Automobil- und Energiewirtschaft

Am 14./15. Mai geht es in Chemnitz um die Mobilitätswende durch Elektro- und Wasserstofffahrzeuge.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Understanding Bioeconomy Systems: Integrating Economic, Organisational and Policy Concepts Kapitel lesen Erstes Kapitel lesen

2020 | OriginalPaper | Buchkapitel

8. Biotechnology Directive: A Major Step in Biotechnology Patent Law in Europe

verfasst von : Li Jiang

Erschienen in: Bioeconomy for Sustainable Development

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Biotechnology has become a new crucial technology of increasing economic growth. Nowadays, biotechnology has been widely applied in the fields of agriculture, pharmaceutical industry, medicine, energy, and environment protection. With the development of new processes in biotechnology, new adjustments are needed from established patent rules. Thus the Directive was drafted by the Commission to meet the demands of biotechnology industry. The Biotechnology Directive had successively treated the patentability of gene-related inventions, the exceptions to patent and moral issues. In addition, the Directive generally achieved the goal of harmonization of patent laws among the member states. To some extent, the Directive simplified the uncertainty of the patent law which is benefit to increase the research investment and development funds, but the remaining issue limiting its wide acceptance have been discussed in this chapter.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel From Genetic Engineering to Gene Editing: Harnessing Advances in Biology for National Economic Development
Nächstes Kapitel Assessing the Emergence of Bioeconomy in Transition Economies by a Future-Oriented Approach: The Case of Poland
Fußnoten
1
Hilderth M, Resilience: Americas Biotechnology Report 2003, Emst & Young, July 2003
 
2
Commission of the European Communities, Report from the Commission to the European Parliament and Council, “An Assessment of the Implications for Basic Genetic Engineering Research of Failure to Publish, or Late Publication of, Papers on Subjects which could be Patentable as Required under Art.16(b) of Directive 98/44/EC on the legal Protection of Biotechnological Inventions” 7(Brussels 2002)
 
3
Communication on Promoting the competitive environment for the industrial activities based on biotechnology within the Community SEC(91) 629 final
 
4
Braendli P, ‘The future of the European patent system’ (1995) International Review of Intellectual Property and Competition Law
 
5
Sommer T, ‘Patenting the animal kingdom? From cross-breeding to genetic make-up and biomedical research’ (2008) International Review of Intellectual Property and Competition Law
 
6
Gervals D, The TRIPS Agreement: Drafting History and Analysis (2nd edn London Sweet& Maxwell, London2003
 
7
MacQueen H, Waelde C and Laurie G, Contemporary Intellectual Property (Oxford 2008, New York)
 
8
Morneault M, ‘Stem Cell Research and Human Cloning: Where Do We Draw The Line?’ (2005) New Eng.L.Rev.523
 
9
Drahos P, ‘Biotechnology patents, markets and morality’ (1999) European Intellectual Property Review
 
10
Braendli P, ‘The future of the European patent system’ (1995) International Review of Intellectual Property and Competition Law
 
11
Genentech Inc. v Wellcome Foundation Ltd (1989) 8 RPC 147; (1988) 15 IPR 423
 
12
Report from the Commission to the Council and the European Parliament, development and implications of patent law in the field of biotechnology and genetic engineering, at 2
 
13
Sommer T, ‘Patenting the animal kingdom? From cross-breeding to genetic make-up and biomedical research’ (2008) International Review of Intellectual Property and Competition Law
 
14
Aerts R J, ‘Biotechnological patents in Europe-functions of recombination DNA and expressed protein and satisfaction of the industrial applicability requirement’ (2008) International Review of Intellectual Property and Competition Law
 
15
Kolle, ‘For the evolution of this in the EPC’ (1974) 5 I.I.C. 140 at 147–148; IBM/Document retrieval [1990]
 
16
Genentech Inc. v Wellcome Foundation Ltd (1989) 8 RPC 147; (1988) 15 IPR 423
 
17
Crespi, ‘Patents on Genes: Can the Issues be Clarified?’ (2000) 5(3) Bio-Science Law Review 199–204, at 199/200
 
18
Icos Corporation/Seven transmembrane receptor [2002] OJEPO 293.307
 
19
Sena G, ‘Directive on Biotechnological Inventions: patentability of discoveries’ (1999) International Review of Intellectual Property and Competition Law
 
20
Zekos G I, ‘Nanotechnology and biotechnology patents’ (2006) Journal of Law & Information Technology
 
21
Amanda Warren-Jones, ‘Patenting DNA: a lot of controversy over a little intangibility’ (2004)Medical Law Review.
 
22
Oser A, ‘Patenting (partial) gene sequence taking particular account of the EST issue’ (1999) International Review of Intellectual Property and Competition Law
 
23
Howlett M J and Christie A F, ‘An analysis of the approach of the European, Japanese and United States Patent Offices to patenting partial DNA sequences (ESTs)’ (2003) Review of Intellectual Property and Competition Law
 
24
Seller’s Application [1980] R.P.C. 103
 
25
Lindley L J, Mutoh’s application [1984] R.P.C. 85
 
26
Paterson, The European Patent System (2nd ed, 2001) para 12-42a
 
27
Brugger v Medicaid [1996] R.P.C. 635 at 661
 
28
Pharmacia v Merck [2002] R.P.C. 775, paras 123–124
 
29
Martin v Millwood [1956] R.P.C. 125 at 139
 
30
The Nuffield Council’s objection to protecting probes, op.cit.n. 8 at para.3.22
 
31
Jones A W, ‘Patenting DNA: a lot of controversy over a little intangibility’ (2004) Medical Law Review
 
32
Jones A W, ‘Patenting DNA: a lot of controversy over a little intangibility’ (2004) Medical Law Review
 
33
Aerts R J, ‘Biotechnological patents in Europe-functions of recombinant DNA and expressed protein and satisfaction of the industrial applicability requirement’ (2008) International Review of Intellectual Property and Competition Law
 
34
Aerts R J, ‘Biotechnological patents in Europe-functions of recombinant DNA and expressed protein and satisfaction of the industrial applicability requirement’ (2008) International Review of Intellectual Property and Competition Law
 
35
Eli Lilly and Co v Human Genome Sciences Inc., [2008] EWHC 2511(Pat)
 
36
First High Court Ruling on Gene Patens, LexisNexis UK legal New Analysis
 
38
Schertenleib D, ‘The patentability and protection of living organisms in European Union’ (2004) European Intellectual Property Review
 
39
Bently L & Sherman B, Intellectual Property Law (2ndedn Oxford, Oxford 2004) 426
 
40
Plant Genetic System/Glutamine synthetase inhibitors, T356/93 (1993) 24 llC 618; [1995] EPOR 357; [1995] OJEPO 545 (TBA)
 
41
Novartis/Transgenic plant G1/98 [1999] EPOR 123, 137 (TBA)
 
42
Novartis/Transgenic plant G1/98 [2000] EPOR 303, 319 (EBA)
 
43
Llewelyn M, ‘The patentability of biological material: continuing contradiction and confusion’ (2000) European Intellectual Property Review.
 
44
Bently L & Sherman B, Intellectual Property Law (2ndedn Oxford, Oxford 2004) 424
 
45
Harvard/Onco-Mouse [1990] EPOR 501
 
46
Harvard/Onco-mouse [2003] OJEPO 473, 499
 
47
Hospital/Contraceptive methods, T820/94 [1995] EPOR 446
 
48
Lubrizol/Hybrid plant, T320/I87 [1990] OJEPO 71.
 
49
Plant Genetic Systems/Glutamine synthetase inhibitors, T356/93 [1995] EPOR 357.
 
50
Novartis/Transgenic plant, T1054/96 [1999] EPOR 123,135(TBA).
 
51
Sommer T, ‘Patenting the animal kingdom? From cross-breeding to genetic make-up and biomedical research’ (2008) International Review of Intellectual Property and Competition Law
 
52
Plant Bioscience/Broccoli, T83/05 [2008] EPOR 14
 
53
Plant Genetics Systems/Glutamine synthetase inhibitors [1995] OJEPO 545 (Board of Appeal)
 
54
Plant Genetics Systems/Glutamine synthetase inhibitors [1995] OJEPO 545 (Board of Appeal)
 
55
Bostyn S J R, ‘The patentability of genetic information carrier’ (1999) Intellectual Property Quarterly
 
56
Donna M Gitter, ‘Led Astray by the Moral Compass: Incorporating Morality into European Union Biotechnology Patent Law’ (2001) 19 Berkeley Journal of International Law 1, 21
 
57
Jones A W, ‘Finding a common morality codex for biotech- a question of substance’ (2008) International Review of Intellectual Property and Competition Law
 
58
Lubrizol/Hybrid plants, T320/87 [1990] EPOR 173
 
59
Howard Florey/Relaxin, T74/91 [1995] EPOR 541
 
60
Crespi R S, ‘The human embryo and patent law-a major challenge ahead’ (2006) European Intellectual Property Review
 
61
Harmaon S H E, ‘From engagement to reengagement: the expression of moral values in European patent proceedings, past and future’ (2006) European Law Review
 
62
HARVARD/Onco-mouse,T19/90, 1990, O.J. EPO 12/1990, 476, and 1992 O.J. EPO 110/1992, 588
 
63
Harvard/Transgenic animal (T-315/03) [2005] E.P.O.R. 31 at 10.5–10.8 [161]--[164]
 
64
Plant Genetic System/Glutamine synthetase inhibitors, T356/93 (1993) 24 llC 618; [1995] EPOR 357; [1995] OJEPO 545 (TBA)
 
65
Plant Genetic System/Glutamine synthetase inhibitors, T356/93 (1993) 24 llC 618; [1995] EPOR 357; [1995] OJEPO 545 (TBA)
 
66
The “Council’s Reasons” for amending the Commission’s 1992 version of the proposed Directive (1992 version, OJ EC C44, at 36 (16 February 1993); OJ EC C101, at 71 (9 April 1994)
 
67
Jones A W, ‘Finding a common morality codex for biotech- a question of substance’ (2008) International Review of Intellectual Property and Competition Law
 
68
Jones A W, ‘Finding a common morality codex for biotech- a question of substance’ (2008) International Review of Intellectual Property and Competition Law
 
69
Opposition Decision re EP 0695351, Edinburgh University. Not published in OJEPO
 
70
University of Edinburgh/Stem Cell Isolation (Edinburgh), T-1079/03 EP 949131742 unreported, July 21, 2003, Opposition Division, at 22
 
71
Claudio Germinario, “The Value of Life” (2004) Patent World 16–18.
 
72
Crespi R S, ‘The human embryo and patent law-a major challenge ahead’ (2006) European Intellectual Property Review
 
73
G-02/06 of the Enlarged Board of Appeal of the European Patent Office
 
74
Chapman P, ‘Rejection of controversial stem cell patent fails to fully clarify law’ M&C (London 28 November 2008)
 
75
Broensword R and Beyleveld D, ‘Is patent law part of the EC legal order? A critical commentary on the interpretation of Article 6(1) of Directive 98/44/EC in Case C-377/98’ (2002) Intellectual Property Quarterly
 
76
Netherlands v European Parliament (c-377/98) [2002] All E.R. (EC)97; [2001] E.C.R. I-7079; [2001] 3 C.M.L.R. 49; [2002] F.S.R.36; (2002) 68 B.M.L.R.1
 
77
West A O, ‘Preimplantation Genetic Diagnosis, the medical exclusion and the biotechnology directive’ (2007) Medical Law International Vol 8 pp. 239–250
 
78
West A O, ‘Preimplantation Genetic Diagnosis, the medical exclusion and the biotechnology directive’ (2007) Medical Law International Vol 8 pp. 239–250
 
79
Unruh B, ‘Scientific breakthrough! No embryonic stem cells needed’ 22 August 2008 World net daily
 
80
Singh HB, Keswani C, Singh SP (Eds.). Intellectual Property Issues in Microbiology (2019) Springer-Nature, Singapore. 425 pages, ISBN- 9789811374654
 
81
Singh HB, Jha A, Keswani C (Eds.). Intellectual Property Issues in Biotechnology. (2016) CABI, Wallingford, UK. 304 pages, ISBN-13: 9781780646534
 
Metadaten
Titel
Biotechnology Directive: A Major Step in Biotechnology Patent Law in Europe
verfasst von
Li Jiang
Copyright-Jahr
2020
Verlag
Springer Singapore
Buch
Bioeconomy for Sustainable Development

Print ISBN: 978-981-13-9430-0

Electronic ISBN: 978-981-13-9431-7

Copyright-Jahr: 2020

DOI
https://doi.org/10.1007/978-981-13-9431-7_8